CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle D
Last week, CAMP4 Therapeutics announced the close of a $100 million Series B round, which will be used to advance their regulatory RNA (regRNA)-focused programs. Their use of regRNA technology provides a unique approach to treating rare conditions like urea cycle disorders.
CAMP4 Therapeutics is bound for the clinical wilderness saddled with an additional $100 million, sealing a series B aimed at expanding the company’s platform and taking a lead asset into phase 1 trials. For now, the company is backpacking solo, but partners may soon join the journey.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--CAMP4 Therapeutics, a biotechnology company harnessing the power of regulatory RNAs to upregulate genes and restore healthy expression, today announced that it has appointed Ann Barbier, M.D., Ph.D., as Chief Medical Officer, responsible for leading all clinical research and development, medical affairs and related functions. Additionally, former Biogen Executive Vice President of R&D, Al Sandrock, M.D., Ph.D., will join CAMP4’s scientific advisory board.